A Study of ARRY-380 in Patients With Advanced HER2+ Cancer

Seagen

Status and phase

Completed

Phase 1

Conditions

Cancer

Treatments

Drug: ARRY-380, HER2 inhibitor; oral

Study type

Interventional

Funder types

Industry

Identifiers

NCT00650572

ARRAY-380-101

Details and patient eligibility

About

This is a Phase 1 study during which patients with advanced HER2+ solid malignancies or HER2+ metastatic breast cancer will receive investigational study drug ARRY-380.

This study has 2 parts. In the first part, patients with advanced HER2+ solid malignancies, who have already received at least one previous standard therapy, will receive increasing doses of study drug in order to achieve the highest dose of study drug possible that will not cause unacceptable side effects. Approximately 30 patients from the US will be enrolled in Part 1 (Completed).

In the second part of this study, patients with HER2+ metastatic breast cancer, who have already received at least one previous standard therapy, will receive the best dose of study drug determined from the first part of the study and will be followed to see what side effects and effectiveness the study drug has, if any, in treating the cancer. Approximately 20 patients from the US will be enrolled in Part 2 (Active, not recruiting).

Enrollment

50 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria (Part 1 and Part 2):

Histological or cytological evidence of HER2+ cancer (Part 1) or HER2+ metastatic breast cancer (Part 2).
Patients should have received at least one previous therapeutic regimen and either no longer are candidates for standard therapy, have no standard therapy available, or choose not to pursue standard therapy (patients with HER2+ breast cancer and with clinical indication for trastuzumab or lapatinib should have received prior therapy with trastuzumab and lapatinib, if available).
Eastern Cooperative Oncology Group (ECOG) performance status (PS) between 0 and 2.
Additional criteria exist.

Key Exclusion Criteria (Part 1 and Part 2):

Uncontrolled or symptomatic brain metastases (patients may be considered adequately controlled if on a stable steroid dose for at least 30 days).
Treatment with an investigational medicinal product or device within 30 days prior to first dose of study drug.
Radiotherapy within 28 days prior to first dose of study drug (not including palliative radiotherapy at focal sites).
Chemotherapy within 21 days prior to first dose of study drug.
Major surgery within 30 days prior to first dose of study drug.
Known positive serology for the human immunodeficiency virus (HIV), hepatitis B and/or active hepatitis C.
Additional criteria exist.